Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04033328 · ClinicalTrials.gov registry record · Phase 1
Study of ORIC-101 in Combination With Enzalutamide
A Phase 1 study, sponsored by ORIC Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT04033328 is a Phase 1 study that was terminated before completion, run by ORIC Pharmaceuticals. The registered enrollment target is 41 participants.
The verdict
NCT04033328, a Phase 1 study, was terminated before completion, sponsored by ORIC Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with enzalutamide (Xtandi®) when administered to patients with metastatic prostate cancer progressing on enzalutamide.
Interventions
- DRUG ORIC-101
- DRUG enzalutamide 40 MG oral capsule [Xtandi]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-10-28 |
| Est. Completion | 2023-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04033328
The ClinicalTrials.gov registry entry for NCT04033328 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ORIC Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ORIC-101 is the first listed.
NCT04033328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04033328 about?
NCT04033328 is a clinical study titled "Study of ORIC-101 in Combination With Enzalutamide". The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with enzalutamide (Xtandi®) when administered to patients with metastatic prostate cancer progressing on ...
What is the current status of trial NCT04033328?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2019-10-28. Estimated completion is 2023-12-04.
What interventions are being tested in trial NCT04033328?
The interventions under investigation include: ORIC-101 (DRUG), enzalutamide 40 MG oral capsule [Xtandi] (DRUG).
Who is sponsoring clinical trial NCT04033328?
This trial is sponsored by ORIC Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.